Regencell Bioscience Holdings Limited is a biotechnology firm specializing in Traditional Chinese Medicine (TCM). Its core activities revolve around the research, development, and market introduction of TCM solutions specifically designed to address neurocognitive disorders and related degeneration. The company places a particular emphasis on conditions such as attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Established in 2014, Regencell Bioscience maintains its primary office in Causeway Bay, Hong Kong.
$RGC has gained 95% since Aug 15, 2026, adding another 2.0% today. @TheBigBerbowski made the initial call on X on Aug 15, 2026 at $5.25. @TheBigBerbowski is worth a follow. Their full record: https://t.co/DlIBU4UlDs https://t.co/X0sq9xObqV
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $0 | — | $-3.58M |
| 2024 | $0 | — | $-4.3M |
| 2023 | $0 | — | $-5.87M |
Stock data for RGC: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics